

Claims:

1. A method of treating a patient having a myocardial infarction comprising administration of a therapeutically effective amount of tissue factor protein antagonist to prevent reocclusion and a thrombolytic agent in a therapeutically effective amount to dissolve a fibrin-platelet clot.
2. A method of treating a patient having angioplasty comprising administration of a therapeutically effective amount of tissue factor protein antagonist to prevent reocclusion and a thrombolytic agent in a therapeutically effective amount to dissolve a fibrin-platelet clot.
3. The method of claim 1 or 2 wherein administration to the patient is by intravenous infusion.
4. The method of claim 1 or 2 wherein administration to the patient is by bolus.
5. The method of claim 4 wherein the bolus is intravenously injected.
6. The method of claim 4 wherein the patient is administered a first bolus containing the tissue factor protein antagonist and subsequently administered a second bolus containing the thrombolytic agent.
7. The method of claim 4 wherein the patient is administered a first bolus containing the thrombolytic agent and subsequently administered a second bolus containing the tissue factor protein antagonist.

8. The method of any one of claims 1 - 4 wherein tissue factor protein antagonist is an antibody.
- 5 9. The method of claim 8 wherein the antibody is a polyclonal antibody.
- 10 10. The method of claim 8 wherein the antibody is a monoclonal antibody.
- 10 11. The method of any one of claims 1-4 wherein said thrombolytic agent is selected from the group consisting of streptokinase, urokinase, prourokinase and tissue-type plasminogen activator.
- 15 12. The method of claim 11 wherein said thrombolytic agent is tissue-type plasminogen activator.
- 20 13. The method of any one of claims 1-3 or 7 wherein the tissue factor protein antagonist is given at a dose of about in the range of 0.01 - 25.0 mg per kg of patient weight and the thrombolytic agent is given at a dose of about in the range of 0.01 - 2.5 mg per kg of patient weight.
- 25 14. A pharmaceutical composition for the treatment of myocardial infarction comprising therapeutically effective amounts of a tissue factor protein antagonist and thrombolytic agent.
15. The pharmaceutical composition of claim 14 wherein the tissue factor protein antagonist is an antibody.
- 30 16. The pharmaceutical composition of claim 14 wherein the thrombolytic agent is selected from the group consisting of

